Instrument Inactif

Communiqués Vivesto AB OTC Markets

Actions

OASMY

US67421W1099

Produits pharmaceutiques

Communiqués

17/09	Vivesto: Positive top-line results in cat study	AQ
17/09	Vivesto reports positive Paccal Vet cat topline results supporting continued clinical development	AQ
15/09	Vivesto: Positive top-line results in dog study	AQ
15/09	Vivesto’s positive dog topline results support continued development and strengthen partnering prospects for Paccal Vet	AQ
13/08	Vivesto: Largely a non-event, key readouts ahead – Q2 review	AQ
01/07	Vivesto: Cat study enrolment completed, results expected in Q4	AQ
01/07	Vivesto completes recruitment in Paccal Vet study in cats and determines maximum tolerated dose	AQ
26/06	Vivesto: Paccal Vet top-line results expected in Q3	AQ
26/06	Vivesto completes recruitment in Paccal Vet dog pilot study – topline results expected Q3 2026	AQ
16/06	Vivesto: Positive data for Cantrixil	AQ
16/06	Vivesto reports positive results from i.v. Cantrixil PK/toxicology study	AQ
05/06	Vivesto appoints Björn Svanström as CFO	AQ
29/05	New number of shares and votes in Vivesto	AQ
26/05	Vivesto: Minor model adjustments	AQ
13/05	Vivesto announces timetable for reverse share split	AQ
07/05	Vivesto: Purring along – Q1 review	AQ
07/05	Vivesto : Minutes AGM 2026 – May 6, 2026 (minutes agm 2026 may 6 2026)	PU
07/05	Report from Annual General Meeting in Vivesto AB	AQ
14/04	Vivesto : Remuneration report 2025 (remuneration report 2025 vivesto ab)	PU
13/04	Vivesto : Auditor’s report – remuneration to group executive management Vivesto 2025 (auditors report remuneration to group executive management vivesto 2025)	PU
01/04	Notice of Annual General Meeting in Vivesto AB	AQ
01/04	The Board of Directors of Vivesto proposes a reverse share split and reduction of the share capital	AQ
13/03	First dogs dosed in Vivesto's PK/toxicology study with Cantrixil	AQ
02/03	Vivesto: Several inflection points approaching – Q4 review	AQ
27/02	New number of shares and votes in Vivesto	AQ